4.2M
XNAS Volume
High volume today
XNAS 25 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 12,562 | 12,560 | - | - | Restricted Stock Unit | |
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.53 per share. | 16 Mar 2025 | 4,628 | 133,205 | - | 0.5 | 2,466 | Common Stock |
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 12,562 | 137,833 | - | - | Common Stock | |
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 25,000 | 134,482 | - | - | Common Stock | |
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share. | 15 Feb 2025 | 9,211 | 125,271 | - | 0.7 | 6,187 | Common Stock |
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 800,000 | 800,000 | - | - | Stock Option (Right to Buy) | |
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 25,000 | 75,000 | - | - | Restricted Stock Unit | |
| David Dornan | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 9,375 | 9,375 | - | - | Common Stock | |
| David Dornan | CHIEF SCIENTIFIC OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share. | 15 Feb 2025 | 4,152 | 5,223 | - | 0.7 | 2,789 | Common Stock |
| David Dornan | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 9,375 | 28,125 | - | - | Restricted Stock Unit | |
| Valerie Malyvanh Jansen | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 17,500 | 52,500 | - | - | Restricted Stock Unit | |
| Valerie Malyvanh Jansen | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 17,500 | 17,500 | - | - | Common Stock | |
| Valerie Malyvanh Jansen | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share. | 15 Feb 2025 | 5,189 | 12,311 | - | 0.7 | 3,485 | Common Stock |
| Valerie Malyvanh Jansen | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 9,375 | 28,125 | - | - | Restricted Stock Unit | |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 300 | 2,400 | - | - | Restricted Stock Unit | |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 9,375 | 10,785 | - | - | Common Stock | |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share. | 15 Feb 2025 | 2,780 | 8,005 | - | 0.7 | 1,867 | Common Stock |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 300 | 8,305 | - | - | Common Stock | |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share. | 15 Feb 2025 | 89 | 8,216 | - | 0.7 | 60 | Common Stock |
| J. Ferra Joseph | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 12,563 | 114,111 | - | - | Common Stock | |
| J. Joseph Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 12,563 | 25,122 | - | - | Restricted Stock Unit | |
| J. Ferra Joseph | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.64 per share. | 16 Dec 2024 | 4,629 | 109,482 | - | 0.6 | 2,963 | Common Stock |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.53 per share. | 15 Nov 2024 | 98 | 1,410 | - | 0.5 | 52 | Common Stock |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 300 | 1,508 | - | - | Common Stock | |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 300 | 2,700 | - | - | Restricted Stock Unit | |
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 12,562 | 37,685 | - | - | Restricted Stock Unit | |
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.61 per share. | 16 Sep 2024 | 4,628 | 101,548 | - | 0.6 | 2,823 | Common Stock |
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 12,562 | 106,176 | - | - | Common Stock | |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.72 per share. | 15 Aug 2024 | 89 | 1,208 | - | 0.7 | 64 | Common Stock |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 300 | 1,297 | - | - | Common Stock | |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 300 | 3,000 | - | - | Restricted Stock Unit | |
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 12,562 | 50,247 | - | - | Restricted Stock Unit | |
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.23 per share. | 16 Jun 2024 | 4,628 | 93,614 | - | 3.2 | 14,948 | Common Stock |
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 12,562 | 98,242 | - | - | Common Stock | |
| R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Timothy P. Clackson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Alan B. Sandler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Darcy Mootz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 300 | 3,300 | - | - | Restricted Stock Unit | |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 300 | 1,097 | - | - | Common Stock | |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.73 per share. | 15 May 2024 | 100 | 997 | - | 3.7 | 373 | Common Stock |
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2024 | 12,562 | 62,809 | - | - | Restricted Stock Unit | |
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.39 per share. | 16 Mar 2024 | 4,773 | 85,680 | - | 4.4 | 20,953 | Common Stock |
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2024 | 12,562 | 90,453 | - | - | Common Stock | |
| Alan B. Sandler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Furlong Tammy | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Furlong Tammy | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.77 per share. | 15 Feb 2024 | 403 | 797 | - | 2.8 | 1,116 | Common Stock |
| Malyvanh Jansen Valerie | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Valerie Jansen Malyvanh | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 70,000 | 70,000 | - | - | Restricted Stock Unit | |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 1,200 | 1,200 | - | - | Common Stock | |
| Dornan David | CHIEF SCIENTIFIC OFFICER | 15 Feb 2024 | 37,500 | 37,500 | - | - | Restricted Stock Unit | ||
| Joseph Ferra J. | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 600,000 | 600,000 | - | - | Stock Option (Right to Buy) | |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 37,500 | 37,500 | - | - | Restricted Stock Unit | |
| David Dornan | CHIEF SCIENTIFIC OFFICER | 15 Feb 2024 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | ||
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 100,000 | 100,000 | - | - | Restricted Stock Unit | |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 1,200 | 3,600 | - | - | Restricted Stock Unit | |
| Darcy Mootz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| J. Joseph Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2023 | 12,563 | 82,664 | - | - | Common Stock | |
| J. Joseph Ferra | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.51 per share. | 16 Dec 2023 | 4,773 | 77,891 | - | 0.5 | 2,434 | Common Stock |
| Joseph J. Ferra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2023 | 12,563 | 75,371 | - | - | Restricted Stock Unit | |
| Joseph J. Ferra | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2023 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Tammy Furlong | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2023 | 53,433 | 53,433 | - | - | Stock Option (Right to Buy) | |
| R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 31,238 | 31,238 | - | - | Stock Option (Right to Buy) | |
| Timothy P. Clackson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 31,238 | 31,238 | - | - | Stock Option (Right to Buy) | |
| Joseph J. Ferra | INTERIM CEO & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.47 per share. | 16 Jun 2023 | 4,773 | 62,312 | - | 1.5 | 7,016 | Common Stock |
| Joseph J. Ferra | INTERIM CEO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 12,563 | 100,496 | - | - | Restricted Stock Unit | |
| Joseph J. Ferra | INTERIM CEO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 12,563 | 67,085 | - | - | Common Stock | |
| Lori Hu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 31,238 | 31,238 | - | - | Stock Option (Right to Buy) | |
| Colin Walsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 31,238 | 31,238 | - | - | Stock Option (Right to Buy) | |
| Joseph J. Ferra | INTERIM CEO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 12,563 | 113,059 | - | - | Restricted Stock Unit | |
| Joseph J. Ferra | INTERIM CEO & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.35 per share. | 16 Mar 2023 | 4,773 | 54,522 | - | 2.4 | 11,217 | Common Stock |
| Joseph J. Ferra | INTERIM CEO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 12,563 | 59,295 | - | - | Common Stock | |
| Joseph J. Ferra | INTERIM CEO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 270,000 | 270,000 | - | - | Stock Option (Right to Buy) | |
| David Dornan | CHIEF SCIENTIFIC OFFICER | 15 Feb 2023 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | ||
| Valerie Malyvanh Jansen | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Joseph J. Ferra | INTERIM CEO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Joseph J. Ferra | INTERIM CEO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 240,000 | 240,000 | - | - | Stock Option (Right to Buy) | |
| David Dornan | CHIEF SCIENTIFIC OFFICER | 06 Jan 2023 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | ||
| Valerie Malyvanh Jansen | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 15,619 | 15,619 | - | - | Stock Option (Right to Buy) | |
| Timothy P. Clackson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 15,619 | 15,619 | - | - | Stock Option (Right to Buy) | |
| Timothy P. Clackson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 17 Jun 2022 | 31,553 | 15,777 | - | 0 | Common Stock | |
| Lori Hu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 15,619 | 15,619 | - | - | Stock Option (Right to Buy) | |
| Colin Walsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 15,619 | 15,619 | - | - | Stock Option (Right to Buy) | |
| Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 12,562 | 125,622 | - | - | Restricted Stock Unit | |
| Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 12,562 | 51,505 | - | - | Common Stock | |
| Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.95 per share. | 16 Jun 2022 | 4,773 | 46,732 | - | 0.9 | 4,534 | Common Stock |
| Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 50,249 | 150,746 | - | - | Restricted Stock Unit | |
| Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 12,562 | 138,184 | - | - | Restricted Stock Unit | |
| Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 50,249 | 50,249 | - | - | Common Stock | |
| Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.26 per share. | 16 Jun 2022 | 19,095 | 31,154 | - | 1.3 | 24,060 | Common Stock |
| Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 12,562 | 43,716 | - | - | Common Stock | |
| Joseph J. Ferra | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.25 per share. | 16 Jun 2022 | 4,773 | 38,943 | - | 1.2 | 5,966 | Common Stock |
| David Dornan | Chief Scientific Officer | 14 Mar 2022 | 230,000 | 230,000 | - | - | Employee Stock Option (right to buy) | ||
| Joseph J. Ferra | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
| Shawn Leland | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 186,500 | 186,500 | - | - | Employee Stock Option (Right to Buy) | |
| Valerie Malyvanh Jansen | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
| Valerie Malyvanh Jansen | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Oct 2021 | 40,000 | 40,000 | - | - | Employee Stock Option (Right to Buy) | |
| Joseph J. Ferra | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 249,104 | 249,104 | - | - | Stock Option (Right to Buy) | |
| Joseph J. Ferra | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 200,995 | 200,995 | - | - | Restricted Stock Unit (RSU) | |
| Richard S. Gaster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 31,238 | 31,238 | - | - | Director Stock Option (Right to Buy) | |
| Lori Hu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 31,238 | 31,238 | - | - | Director Stock Option (Right to Buy) | |
| Colin Walsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 31,238 | 31,238 | - | - | Director Stock Option (Right to Buy) |